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Abstract:
Immune thrombocytopenia (ITP) is an acquired autoimmune condition characterized by both reduced platelet
production and the destruction of functionally normal platelets by sustained attack from the immune
system. However, the effect of prolonged ITP on the more immature hematopoietic progenitors remains an
open area of investigation. Using a murine in vivo model of extended ITP, we reveal that ITP progression
drives considerable progenitor expansion and bone marrow (BM) remodelling. Single cell assays using
Lin-Sca1+c-Kit+CD48-CD150+ long-term hematopoietic stem cells (LT-HSCs) revealed elevated LT-HSC
activation and proliferation in vitro. However, the increased activation did not come at the expense of
LT-HSC functionality as measured by in vivo serial transplantations. ITP progression was associated with
considerable BM vasodilation and angiogenesis, as well as a 2-fold increase in local production of
CXCL12; a cytokine essential for LT-HSC function and BM homing expressed at high levels by LepR+ BM
stromal cells. This was associated with a 1.5-fold increase in LepR+ BM stromal cells and a 5.5-fold
improvement in progenitor homing to the BM. Whereas the increase in stromal cells was transient and
reverted back to baseline after platelet count returned to normal, vasculature changes in the BM
persisted. Together, these studies demonstrate that LT-HSCs expand in response to ITP, and that LT-HSC
functionality during sustained hematopoietic stress is maintained through an adapting BM
microenvironment.
Conflict of interest: No COI declared
COI notes: 
Preprint server: No; 
Author contributions and disclosures: O.J.H wrote the manuscript, all authors interpreted data and read
and edited the final manuscript. O.J.H, I.S.H and D.G.K designed experiments. O.J.H performed all
experiments with assistance from G.F.R, J.P.H, K.H, A.P.S, D.G.K and I.S.H.
Non-author contributions and disclosures: Yes; The authors thank the staff of the Biological Services
Facility for animal husbandry, TissueGnostics application specialists and the staff of the Technological
Facility Imaging and Cytometry Laboratory for assistance with flow cytometry and confocal microscopy.
Additionally, the authors thank Tess Stanley, Katiuska Pulgar Prieto and Maria Abril Arrendondo Garcia
for experimental assistance. This work was supported by funding from the White Rose BBSRC DTP and the
British Heart Foundation (PG/16/26/32099).
Agreement to Share Publication-Related Data and Data Sharing Statement: For original data, please
contact ian.hitchcock@york.ac.uk
































































































































Bone Marrow Remodelling Supports Hematopoiesis in 





, Gulab Fatima Rani
1









, David G Kent
1
, Paul G Genever
1
, Ian S Hitchcock
1*
 
1 York Biomedical Research Institute, Department of Biology, University of York, York, United 
Kingdom 
2Technology Facility, Department of Biology, University of York, York, United Kingdom 
3Centre for Haematology, Department of Immunology and Inflammation, Department of Medicine, 
Hammersmith Hospital, Imperial College London, London, United Kingdom 
*Correspondence to: Ian S Hitchcock  
Ian S Hitchcock, PhD 
Professor of Experimental Hematology 
Department of Biology 
University of York 
Heslington, York 
YO10 5DD, United Kingdom 
ian.hitchcock@york.ac.uk,  
+44 (0)1904 328914 
 
Running Title: Bone Marrow Remodelling in Chronic ITP 
Main Text Word Count: 3847 
Abstract Word Count: 219 
Figure Count: 5 



































































































































Key Points  
 Sustained ITP activates and increases the number of functional LT-HSCs 
 The remodelled ITP bone marrow enhances hematopoiesis  
Abstract 
Immune thrombocytopenia (ITP) is an acquired autoimmune condition characterized by both reduced 
platelet production and the destruction of functionally normal platelets by sustained attack from the 
immune system. However, the effect of prolonged ITP on the more immature hematopoietic 
progenitors remains an open area of investigation. Using a murine in vivo model of extended ITP, we 
reveal that ITP progression drives considerable progenitor expansion and bone marrow (BM) 
remodelling. Single cell assays using Lin-Sca1+c-Kit+CD48-CD150+ long-term hematopoietic stem 
cells (LT-HSCs) revealed elevated LT-HSC activation and proliferation in vitro. However, the 
increased activation did not come at the expense of LT-HSC functionality as measured by in vivo 
serial transplantations. ITP progression was associated with considerable BM vasodilation and 
angiogenesis, as well as a 2-fold increase in local production of CXCL12; a cytokine essential for LT-
HSC function and BM homing expressed at high levels by LepR+ BM stromal cells. This was 
associated with a 1.5-fold increase in LepR+ BM stromal cells and a 5.5-fold improvement in 
progenitor homing to the BM. Whereas the increase in stromal cells was transient and reverted back 
to baseline after platelet count returned to normal, vasculature changes in the BM persisted. 
Together, these studies demonstrate that LT-HSCs expand in response to ITP, and that LT-HSC 



































































































































Increased destruction and decreased production of functionally normal platelets is a hallmark of 
Immune Thrombocytopenia (ITP), which manifests as a bleeding tendency 1-3. The majority of ITP 
patients develop serum platelet specific autoantibodies that target platelets for destruction and are 
primarily against platelet glycoprotein (GP) IIb/IIIa (CD41/CD61), GPIb/IX (CD42c/CD42a), GPV 
(CD42d) and GPIa/IIa (CD49b) 4-7. Of these, autoantibodies against CD41/CD61 are the most 
common 6,7. The spleen is the major site of platelet clearance, which is primarily mediated through 
phagocytosis by splenic macrophages or dendritic cells 8,9. ITP patients can be classified as ‘newly 
diagnosed’ (< 3 months) or ‘persistent’ (< 12 months) which is more common in children, as well as 
‘chronic’ (> 12 months) which is more common in adults 10,11. 
During conditions of chronic hematopoietic stress, such as infection and inflammation, hematopoietic 
stem cells (HSCs) are activated to meet the increased demand in blood cell production 12,13. Exit from 
quiescence has been previously associated with a loss in regenerative capacity and may eventually 
cause pancytopenia 14-16. During ITP, the requirement for HSC differentiation is twofold. Firstly, the 
increased platelet demand caused by autoimmune-mediated platelet destruction drives 
megakaryopoiesis 17-20. Secondly, sustained immune system activation driving platelet destruction 
requires replenishment from progenitors 12,13,21. Despite this, there have been no reports of HSC 
exhaustion or pancytopenia in chronic ITP patients, suggesting that HSCs may receive additional 
support. 
Recent evidence shows that the bone marrow (BM) microenvironment provides supportive, rather 
than instructive input for HSC differentiation 22. Furthermore, the microenvironment is pliable, and can 
contribute to disease progression by driving the expression of proliferative/pro-inflammatory factors or 
by downregulating factors which traditionally support HSC function. Such changes may be induced by 
the presence of infection 23,24, the development of malignancy 25,26 or the administration of drugs 27. 
Whether the BM microenvironment actively remodels itself in response to various chemical or cellular 
insults to resolve and/or minimise hematopoietic stress remains unclear.  
Antibody mediated platelet destruction can be recreated in vivo by the administration of anti-platelet 
antibodies to cause thrombocytopenia 28. This is known as the passive transfer model of ITP, and its 
































































































































antibodies spanning 1-2 weeks 31-35. To better model sustained ITP, we extend this model to 4 weeks, 
showing that the increased demand on hematopoiesis is met by an increase in the number of 
functional HSCs. We hypothesise that this is achieved through an interactive and iterative relationship 
between differentiating HSCs and an adapting supportive BM microenvironment in an effort to 
maintain homeostasis.  
Methods 
Mice 
Mice used in this study were female wild type (WT) C57Bl/6J (B6)-CD45.1 or CD45.2 mice unless 
otherwise stated. Cxcl12DsRed/+ knock-in mice were previously bred onto a B6 genetic background and 
were generated by recombining DsRed-Express2 into the endogenous Cxcl12 locus as previously 




41-CD45.1 mice aged between 7-9 months of age were used as recipients for low dose Lin-
Sca1+c-Kit+CD48-CD150+ long-term hematopoietic stem cell (LT-HSC) transplantation experiments. 
All mice were bred and housed under specified pathogen-free conditions. All animal procedures were 
approved by the University of York Animal Welfare and Ethical Review Board and carried out under 
UK Home Office licence (PPL P24552FC1). Animals were killed by CO2 asphyxia and cervical 
dislocation, or overdose of anaesthesia and exsanguination. Mice were randomly allocated to the IgG 
or anti-CD41 group and downstream sample analysis was performed blinded. Primers for genotyping 
of the Cxcl12DsRed allele: 5’-AAGAAGCCCGTGAAGCTGC-3’ and 5’-TCCTCGTTGTGGGAGGTGAT-
3’. 
Passive ITP Model 
Mice were administered anti-mouse CD41 antibody (clone MWReg30; BD Pharmingen) to selectively 
deplete platelets (or IgG1 to act as a control) via intraperitoneal injection every 48 h for up to 4 weeks 
(duration dependent on the experiment). Concentration of anti-CD41/IgG1 ranged between 0.2-0.4 
mg/kg as indicated in Figure 1. As described previously, antibody dose escalation is necessary to 
maintain thrombocytopenia over time 34. In our study, 0.2 mg/kg anti-CD41 was sufficient to maintain 
thrombocytopenia for the first 2 weeks, followed by an increase of 0.1 mg/kg per week thereafter.  
































































































































WT (CD45.2) donor mice were injected with anti-mouse CD41 antibody, whilst WT (CD45.1) donor 
mice were injected with IgG1 for 4 weeks (as described above). CD45.1 recipient mice were 
administered total body gamma radiation with two doses of 5.5 Gy, 24 h apart (lethal irradiation). For 
primary transplants, flushed BM from donor mice was prepared by mixing CD45.1 and CD45.2 BM 
cells in a 3:1, 1:1, and 1:3 ratio and resuspended in sterile PBS. A total of 5x106 cells in a final volume 
of 200 µL was injected into the tail vein of each of the recipient mice. For secondary transplants, 
2x107 BM cells from primary transplant donors (pooled within each group) were further transplanted 
into CD45.1 recipient mice. All recipient mice were administered oral antibiotic Baytril (Bayer, 
Leverkusen, Germany) in drinking water for 14 days post-transplant as a prophylactic treatment 
against bacterial infection. Recipient mice were bled at 4, 8, 12, 16 and 20 weeks to monitor donor 
chimerism and relative mature cell production by flow cytometry. Full details of antibodies used and 
flow cytometry methodology are available in the Supplementary Methods. 
Cell Sorting and Transplantation Experiments 
Lin- donor cells were immunomagnetically enriched prior to cell sorting based upon the negative 
expression of lineage markers via the EasySep Mouse Hematopoietic Progenitor Cell Isolation Kit 
(19856, StemCell Technologies) according to the manufacturer’s instructions. Following enrichment, 
cells were stained for progenitor markers as described in the Supplementary Methods. 
For homing assays, approximately 15,000 Lin- Sca1+c-Kit+ (LSK) cells from naïve CD45.1 mice were 
administered in 100 µL sterile PBS per recipient mouse via tail vein injection. Recipient mice were 
lethally irradiated CD45.2 mice, previously administered anti-CD41 or IgG for 4 weeks. 36 h later, BM 
was harvested and stained for donor cells followed by flow cytometry analysis as described in the 
Supplementary Methods. 
For low dose HSC transplantation experiments, 100 LT-HSCs from either 4 week anti-CD41 or IgG 
injected CD45.2 mice were bulk sorted into 1 mL of PBS, and diluted so that each sub-lethally 
irradiated (one dose of 3.6 Gy) B6-W41/W41-CD45.1 mouse received either 10 or 3 LT-HSCs. 
Recipient B6-W41/W41-CD45.1 mice were bled 4, 8 or 11 weeks post transplantation and peripheral 
blood analysed to determine levels of chimerism as described in the Supplementary Methods. The 
































































































































confirm whether mice with < 1% chimerism (trace chimerism) would progress to develop > 1% 
chimerism with time. Mice with trace chimerism are highlighted in the results. 
For in vitro LT-HSC assays, 1 LT-HSC was sorted per well of a round bottom 96-well plate, with each 
well containing 50 µL of LT-HSC media as described in the Supplementary Methods. 
Cells were sorted using a four laser Beckman Coulter Astrios Eq sorter. 
Statistics 
Statistical analyses were performed using GraphPad Prism software (Version 8.4.3). In statistical 
graphs, data points indicate individual samples and bars represent mean values ± SD. P < 0.05, *P < 
0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, whilst non-significant values (P > 0.05) are not shown. 
P values are reported in the figure legend. 
Results 
ITP Progression Drives Hematopoietic Progenitor Expansion  
To determine the long-term impact of ITP on hematopoiesis, a model for sustained ITP was 
established by repeated (every 48 h) intraperitoneal injection of mice with a monoclonal rat anti-
mouse CD41 antibody or rat IgG1 isotype control for a period of 4 weeks (Figure 1). From 2 weeks, 
increased doses of rat anti-CD41 antibody were necessary to maintain thrombocytopenia, presumably 
to counteract compensatory thrombopoiesis 34 and/or antibody generation against the injected rat 
IgG1 antibody. Hereafter, mice treated with anti-CD41 are referred to as the ‘ITP’ group; mice treated 
with IgG1 are referred to as the ‘control’ group. 
This passive transfer model maintains severe thrombocytopenia (defined here as a mean platelet 
count below 200x109/L), from a mean resting platelet count of 865x109/L. Mice in the ITP group had a 
platelet count range of 57-327x109/L, whilst controls had a platelet count range of 584-1402x109/L. 
Additionally, mice with ITP had an increase in mean platelet volume indicating a higher platelet 
turnover (Figure 1Ai). Plasma thrombopoietin levels were not affected by ITP, although an increase in 
the number of BM megakaryocytes was observed at later time points (Figure 1B-C). As inflammatory 
factors are known to drive emergency megakaryopoiesis independently of thrombopoietin 37, the 
plasma and BM supernatant were analysed. Biological processes involved in the inflammatory 
































































































































plasma and the BM (Figure 1D and Figure S1). Upregulation of these biological processes were 
higher in the BM than the plasma which was of interest as inflammation and MAPK signalling have 
previously been shown to affect LT-HSC quiescence and function 37,38.  Additionally, some biological 
processes and reactome pathways also shown to affect LT-HSC quiescence and function such as IL-
1 signalling and smooth muscle cell proliferation (such as VEGF, MMP2, WISP1 and IGFBP-3) were 
uniquely upregulated in the BM (Figure 1D and Figure S1) 39-43.  
To test whether sustained ITP affects hematopoietic progenitors, mice in the ITP group and controls 
were compared by flow cytometry. Whilst ITP had no effect on total BM cellularity (Figure 2A), ITP 
caused a 1.3-fold expansion in the percentage of BM-derived Lin-Sca1-c-Kit+ (LK cells, enriched for 
myeloid progenitors) and 1.7-fold expansion in LSK cells, which are enriched for HSCs (Figure 2Bi 
and ii). Progenitor expansion in the spleen was also observed (Figure S2C-E), with a 2 and 2.9-fold 
expansion in the LK and LSK populations, respectively, suggesting the presence of extramedullary 
hematopoiesis in ITP. The LSK population was subdivided further using SLAM markers 44, with the 
largest expansion in the LT-HSC fraction (2.8-fold in the BM and 9.7-fold in the spleen) (Figure 2Bv). 
Gating strategies of analysed BM and splenic populations are shown in Figure S2A-B. 
To determine the functional effect of ITP on LT-HSCs, single LT-HSCs from mice in the ITP group or 
controls were isolated and cultured in conditions which maintain LT-HSC activity (Figure 2B) and 
analysed for changes in cell division, colony size and cell phenotype 45,46. LT-HSCs from mice with 
ITP proliferated faster, with less time taken to complete first, second and third division (Figure 2C). 
This faster division formed larger colonies at day 10 of culture (Figure 2D), which were driven by an 
increase in LSK progenitors (Figure 2Ei). However, despite the overall increase in number of cells per 
clone, ITP did not alter the proportion of differentiated and stem/progenitor cells within clones, 
suggesting that progenitor expansion was not accompanied by differentiation or self-renewal defects 
(Figure 2Eii-iii). Our results indicate that sustained ITP induces the cycling of phenotypic LT-HSCs, 
causing an expansion of hematopoietic progenitors without compromising LT-HSC function. 
Sustained ITP Increases the Number of Functional LT-HSCs 
In order to assess the in vivo functional capacity of the expanded progenitor compartment, 
competitive transplantation assays were performed using 5x106 whole BM cells from ITP and control 
































































































































weeks using 2x107 pooled whole BM cells from mice within each ratio group. In the 1:1 group (Figure 
3C), the contribution of ITP donors to peripheral chimerism increased to 63 ± 6% (mean values ± SD), 
accompanied by an expanded contribution to the BM LT-HSC phenotype at 85 ± 10%. Secondary 
transplantation data similarly showed an increased contribution by donor cells derived from the ITP 
group to mature cell production. Together, these transplantation data demonstrate the existence of an 
expanded, self-renewing pool of functional LT-HSCs in the BM of mice with sustained ITP. 
In order to test LT-HSC functional capacity more directly, we next transplanted limiting numbers of 
highly purified LT-HSCs isolated using the Lin-Sca1+c-Kit+CD48-CD150+ phenotype. Either 3 or 10 LT-




41-CD45.1 mice (Figure 3E). Whereas 20% of mice receiving 3 LT-HSCs and 40% of mice 
receiving 10 LT-HSCs from the control group were positive, none of the mice receiving LT-HSCs from 
mice with ITP were repopulated (Figure 3F), suggesting that the LT-HSC phenotype in the ITP group 
does not contain as high a frequency of functional LT-HSCs.  
ITP Progression Drives Physical and Biochemical Changes Within the BM HSC Microenvironment 
LT-HSC function is maintained through cytokine-cytokine receptor interactions and direct cell-cell 
contact between the LT-HSC and components of the perivascular BM microenvironment, including 
endothelial cells and LepR+ stromal cells 36,47,48. As sustained ITP causes expansion and functional 
changes in LT-HSCs, we next assessed whether this was accompanied by alterations in the BM 
microenvironment. Immunofluorescence microscopy identified significant changes in non-
hematopoietic components of the HSC BM microenvironment, which were associated with ITP 
progression (Figure 4). Mice with 4 week ITP had a 2-fold increase in sum vessel area, which was 
attributed to an increase in average vessel area rather than any changes in vessel number. Effects 
were also observed at an earlier (2 week) time point, with a 1.5-fold increase in sum vessel area with 
no change in vessel number (Figure S3). Furthermore, at 4 weeks there was a significant LepR+ 
stromal cell expansion (1.5-fold increase), whilst there were no changes in stromal cell number at 2 
weeks. 
To explore whether this remodelling of the BM microenvironment was reversible following recovery 
from thrombocytopenia, mice were allowed to recover for 4 weeks (‘ITP Recovered’ group) prior to 
































































































































day 18 after the final anti-CD41 antibody injection (Figure S4). Despite the amelioration of 
thrombocytopenia, the substantial structural differences observed in the BM vasculature persisted 
with a further 1.5-fold increase in sum vessel area relative to the initial ITP group. In these mice, a 
significant increase in vessel number was observed as opposed to a further increase in average 
vessel area (Figure 4C). Conversely, numbers of LepR+ perivascular stromal cells reverted back to 
control levels, suggesting that stromal cell expansion was transient (Figure 4B). 
Since perivascular LepR+ stromal cells are a major source of factors influencing LT-HSC function, 
including key microenvironment factors CXCL12, SCF and Angiopoietin-1 36,47,49,50, and share the 
same microenvironment as LT-HSCs 47,51,52, we hypothesised that a transient increase in LepR+ 
stromal cells support LT-HSCs in response to sustained ITP. We measured the expression of Cxcl12, 
Kitl and Angpt1 in the BM and found that Cxcl12 expression transiently increased to 2-fold levels in 
the ITP group (Figure 5A), but there were no significant changes in Kitl or Angpt1 (Figure S5B). 
Confocal imaging of the BM microenvironment from Cxcl12DsRed/+ reporter mice from an ITP group 
relative to a control group of mice revealed an increase in perivascular Cxcl12 expression in mice 
from the ITP group (Figure 5B), and that this was driven by the expansion of LepR+ stromal cells 
(Figure S5A). CXCL12 levels were increased 1.8-fold in the BM supernatant of mice with ITP, but not 
in circulation or spleen, confirming a BM specific elevation in CXCL12 (Figure 5C). As CXCL12 has 
an essential role in progenitor homing to the BM 53-56, we hypothesised that mice with ITP would show 
an increased potential for progenitor homing (Figure 5D). Flow cytometry analysis of recipient BM 
revealed that naïve LSKs homed preferentially (5.5-fold increase) to the BM of irradiated mice with 
ITP relative to controls. Together, the data shows that the BM actively remodels in response to ITP 
progression to create a site preferential for hematopoiesis. Whilst the expansion in LepR+ stromal 
cells and associated CXCL12 expression was transient, vasculature changes persisted, the 
consequences of which are unknown. 
Discussion 
Whilst the mechanisms behind the development and maintenance of thrombocytopenia have been 
the subject of intensive research, the wider long-term effects of ITP progression are unclear. Here, we 
establish a model for investigating the effect of ITP progression on hematopoiesis and identify a 
































































































































BM microenvironment. Functional assays demonstrated an increased proliferation and self-renewal 
potential of LT-HSCs, but also indicated a shift in LT-HSC frequency within the LT-HSC phenotype. 
Assessment of the BM microenvironment identified alterations in key mediators of LT-HSC function, 
including an increase in total blood vessel area and a specific increase in LepR+ stromal cells.  
Together, these changes in LT-HSC activation and BM remodelling combine to counteract the stress 
of sustained ITP to ensure homeostasis within the hematopoietic system. 
The murine ITP model we present shares a number of features with the clinical progression of chronic 
ITP such as increased megakaryopoiesis whilst maintaining normal circulating thrombopoietin levels 
17,19,20,57, giving us confidence that our model was an appropriate choice to study the effect of 
sustained ITP on hematopoiesis. Although increased megakaryopoiesis has been previously reported 
to occur as soon as 24 h after anti-CD41 injection 58, we did not observe increased megakaryopoiesis 
until 4 weeks of injections. Cytokine analysis of BM and plasma samples at 4 weeks revealed an 
upregulation of proteins involved in the inflammatory response, which has been previously shown to 
drive megakaryopoiesis 37. As the cytokine signature in the ITP BM appeared to be more divergent 
from controls than the periphery, and that several upregulated biological processes and pathways 
have been previously shown to affect LT-HSC function 38-40, we asked if sustained ITP may affect 
hematopoiesis more broadly. 
The expansion in stem and progenitor cell numbers in ITP in combination with the increase in 
proliferation observed in single LT-HSC in vitro assays suggests that LT-HSCs might be activated in 
response to ITP. Competitive transplantation assays revealed that ITP drives an expansion of LT-
HSCs with durable self-renewal, suggesting that this activation did not compromise LT-HSC activity. 
However, caution is needed when interpreting the relative numbers and activation status of LT-HSCs 
in diseased states. Whereas whole BM competitive transplants allow LT-HSC activity to be assessed 
in an unbiased fashion and indicate that numbers of functional LT-HSC are increased, experiments 
assume that the expression of cell surface markers are not altered as a result of the experimental 
conditions. Indeed, it has been reported that during immune stimulation, BM cells have increased 
expression of Sca1 and CD150, causing non-HSC populations to appear in gates expected to be 
enriched in LT-HSC populations 59. This can lead to dilution of experimental LT-HSCs vs control LT-
HSCs when performing downstream experiments. Our low dose LT-HSC transplantation experiments 
































































































































HSCs from ITP CD45.2 mice failed to repopulate compared to control CD45.2 mice. Together these 
data indicate that LT-HSCs might reside outside the traditional phenotype and that the LT-HSC 
phenotype is contaminated with a larger proportion of non-HSCs in an ITP setting.   
It has recently been shown that progenitors activate and proliferate in response to acute antibody 
mediated thrombocytopenia 33. However, when ITP is extended to 2 weeks, LT-HSC functionality was 
impaired during serial transplants. This discrepancy with our results is potentially due to differences in 
experimental setup. Ramasz et al 33 performed a primary competitive transplant using 300 LT-HSCs 
from mice with sustained ITP and 5x105 BM competitor cells from controls. After 16 weeks, they 
transplanted 300 ITP LT-HSCs from primary recipients into secondary recipients alongside 5x105 
fresh BM competitor cells. The decreased contribution to peripheral blood reconstitution after each 
round of competitive transplant can be explained by our observation that the traditional LT-HSC 
phenotype is contaminated with a larger proportion of non-HSCs in ITP. However, when analysing the 
LT-HSC pool as a whole (e.g. using unbiased whole BM transplants), LT-HSC functionality is 
increased and preserves hematopoiesis long-term.    
The ability of LT-HSCs to maintain functionality in conditions of hematological stress is essential for 
the preservation of hematopoiesis long term. When LT-HSCs are unable to meet the increased 
demand such as in chronic infection 23,24 or the development of malignancy 25,26, LT-HSCs exit 
quiescence and pancytopenia may arise. The increase in the functional LT-HSC pool in ITP therefore 
presents an intriguing dichotomy and we studied the HSC BM microenvironment to determine 
whether beneficial changes in cell extrinsic factors may occur. ITP progression was associated with 
vasodilation and angiogenesis as well as LepR+ stromal cell expansion. The stromal cells maintained 
their classically defined perivascular location and therefore close/adjacent proximity to LT-HSCs 
36,49,60 and their expansion was associated with an increase in CXCL12, which has a crucial role in 
maintaining LT-HSC function, including retention in the BM 36,54,55, repopulating activity 61 and 
quiescence 56,62. Furthermore, this increase in CXCL12 was BM specific and was expected to be 
primarily derived from LepR+ stromal cells 36,60, which we confirmed by confocal microscopy. 
Intriguingly, LepR+ stromal cell number reverted back to levels seen in control mice after recovery 
from ITP, suggesting that thrombocytopenia may indirectly feedback to increase LT-HSC support 
































































































































The BM is the primary and preferential site for steady state hematopoiesis in healthy adults, which is 
maintained by complex and multifactorial interactions from many different niche components 63. 
Extramedullary hematopoiesis during infection or malignancy is often associated with loss of BM 
CXCL12 signalling 23,26,64-66. Our observation that ITP progression coincides with a transient increase 
in BM CXCL12 expression and associated increase in LT-HSC BM homing may be an important 
mechanism to maintain LT-HSC functionality in conditions of elevated differentiation pressure, which 
is essential for maintenance of homeostasis long-term. As BM sinusoids are the preferred sites of 
progenitor homing due to low blood flow velocities and low wall shear rates 67, it is possible that the 
increase in average vessel area in ITP would further reduce blood flow velocity and aid progenitor 
homing. As discussed, it has been shown that progenitors activate and proliferate in response to 
acute antibody mediated thrombocytopenia, driven by the relocalisation of SCF from the cytoplasm to 
the cell membrane of megakaryocytes 33. Interestingly, this was not accompanied by an increase in 
total BM Kitl expression, suggesting that the proliferative effect on progenitors was post-
transcriptionally regulated. In addition to its proliferative effects, SCF is essential for LT-HSC function 
47,48. We have not assessed membrane bound SCF expression in our model of sustained ITP, which 
may present a further mechanism acting to preserve LT-HSC functionality during sustained ITP. 
Our research therefore points to a concerted effort from various components of the BM 
microenvironment to create a nurturing environment maximising megakaryopoiesis whilst minimising 
LT-HSC exhaustion. BM examination is not routinely performed for chronic ITP patients 10; it is 
therefore possible that significant changes in BM architecture can occur which requires further 
investigation. As we have only tested a single anti-CD41 antibody, it is important to investigate 
whether the effects on hematopoiesis and the BM microenvironment are comparable with other 
antiplatelet antibodies, such as anti-CD61 which are also common in ITP patients 6,7. Future studies 
should also address the effect of T cell mediated autoimmunity on hematopoiesis and the BM 
microenvironment, as our model of sustained ITP is T cell independent. This is of relevance as a 
minority of patients do not display autoantibodies, and in these patients ITP is thought to be driven 
through cell-mediated autoimmunity 21. 
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Figure Legends 
Figure 1. Repeated intraperitoneal injection of mice is a model for sustained ITP. A) A single 
intraperitoneal injection of anti-CD41 antibody (delineated by an arrow) every 48 h induces severe 
thrombocytopenia associated with an increase in platelet mean volume (MPV). For routine monitoring 
of ITP induction, mice were bled 24 h after injection. N = 5-10, P values calculated by a Two-way 
ANOVA with Sidak’s multiple comparison test. B) Circulating thrombopoietin (TPO) levels during ITP 
progression (control vs 2 week ITP P > 0.99, control vs 4 week ITP P > 0.99, 2 week ITP vs 4 week 
ITP P > 0.99). N = 4-5 (2 independent experiments). P values calculated by a Kruskal-Wallis test with 
Dunn’s multiple comparisons test. Ci) BM megakaryocyte (Mk) numbers during ITP progression 
(control vs 2 week ITP P > 0.99, control vs 4 week ITP **P = 0.0069, 2 week ITP vs 4 week ITP P = 
0.10). N = 5-8 (2 independent experiments). P values calculated by a Kruskal-Wallis test with Dunn’s 
multiple comparisons test. ii) Representative hematoxylin and eosin stained diaphysis BM sections 
from WT femurs with Mks indicated by yellow stars. Images were obtained using the Zeiss 
AxioScan.Z1 slide scanner. D) Gene Ontology terms within the biological process domain and 
reactome pathways identified by STRING analysis of upregulated cytokines in the i) BM and ii) 
plasma of mice with 4 week ITP relative to control. Cytokine analysis was performed using the 
































































































































Figure 2. Sustained ITP drives progenitor expansion and LT-HSC proliferation. A) Total cell 
counts from flushed BM P = 0.46 (Mann-Whitney test). N = 7, (2 independent experiments). B) Flow 









(Multipotent Progenitors, MPP); P = 0.068, iv) 
LSK CD48-CD150- (Short Term HSC, ST-HSC); *P = 0.019, v) LSK CD48-CD150+ (Long Term HSC, 
LT-HSC); ***P = 0.0005. N = 13 (3 independent experiments), P values were calculated by Mann-
Whitney tests. B) Experimental outline for C-E. C) Cumulative time taken for a single LT-HSC to 
complete first (i), second (ii), and third (iii) division. N = 4-5 (2 independent experiments), P values 
calculated by a Two-way ANOVA with Sidak’s multiple comparison test. D) Colony size after 10 days 
in culture (*P = 0.020). N = 3-4 (representative of 2 independent experiments). P values calculated by 
a Two-way ANOVA. Colonies were categorised as very small (< 50), small (51-500), medium (501-
10,000) or large (> 10,000). E) After 10 days in culture, colonies were analysed by flow cytometry for 
the expression of Lineage and LSK markers. LSK numbers (i, **P = 0.006) and frequency (ii, P = 
0.92). Frequency of Lin+ cells (iii, P = 0.55). P values were calculated by Mann-Whitney tests. n = 143 
and n = 208 clones from controls and mice with sustained ITP, respectively. N = 3 (representative of 2 
independent experiments). All data shows mean values ± SD with the exception of E, which shows 
mean values ± SEM. 
Figure 3. Sustained ITP increases the frequency of functional LT-HSCs in vivo. A) Experimental 
outline for B-D. Bi, Ci and Di) peripheral blood from primary recipients 4-20 weeks after 
transplantation. Bii, Cii and Dii) analysis of BM from primary recipients 20 weeks after 
transplantation. Biii, Ciii and Diii) analysis of peripheral blood from secondary recipients 4-20 weeks 
after transplantation. Biv, Civ and Div) analysis of BM from secondary recipients 20 weeks after 
transplantation. The dotted line shows the expected ratio if ITP had no effect on chimerism; for 
primary recipients this was calculated based upon the transplanted ratio of donor cells, for secondary 
recipients this was calculated based upon the end point of the primary recipients. N = 5 per recipient 
group. E) Experimental outline for F. F) After 11 weeks, 2/9 recipients receiving 3 control LT-HSCs 
and 2/5 recipients receiving 10 LT-HSCs experienced chimerism, whilst 0 recipients receiving ITP LT-
HSCs experienced chimerism, P = 0.013. P value was calculated by a Chi-squared test. A successful 
































































































































10 control LT-HSCs showed > 1% CD45.2 chimerism, whilst 1 mouse showed trace amounts of 
chimerism (< 1%) as marked by an asterisk (*). All data shows mean values ± SD. 
Figure 4. Sustained ITP remodels the BM microenvironment. ITP progression was associated 
with blood vessel structural changes and reversible changes in stromal cell number. Mice were 
treated with IgG (control) or anti-CD41 (ITP) for 4 weeks. A further group of ITP mice were allowed to 
recover for a further 4 weeks after the last injection of anti-CD41, where platelet count returned to 
normal by day 18 (‘ITP Recovered’ group). All data shown from controls and mice with ITP are 
representative of 3 independent experiments, whilst the data from ITP Recovered mice is 
representative of 1 independent experiment. A) Representative confocal images of control, ITP and 
ITP Recovered diaphysis BM from WT femurs. B) Relative numbers of LepR+ stromal cells were 
inferred by comparing total LepR staining between groups. Staining was quantified by exporting the 
LepR channel images as TIFFs and quantifying total staining relative to controls using ImageJ 
software. Control vs ITP *P = 0.018, control vs ITP Recovered P = 0.91, ITP vs ITP Recovered **P = 
0.0021. P values were calculated by a Kruskal-Wallis test with Dunn’s multiple comparison test. N = 
4-9. Values show mean values ± SD, with an average of 10 images analysed per mouse. C) Vessel 
analysis showing: i) Sum vessel area (control vs ITP ****P < 0.0001, control vs ITP Recovered ****P < 
0.0001, ITP vs ITP Recovered ***P = 0.0001), i) Average vessel area (control vs ITP ****P < 0.0001, 
control vs ITP Recovered ****P < 0.0001, ITP vs ITP Recovered P = 0.066), ii) Vessel number 
(control vs ITP P > 0.99, control vs ITP Recovered ***P = 0.0008, ITP vs ITP Recovered ***P = 
0.0007). Vessel information was quantified using StrataQuest analysis software (TissueGnostics). P 
values were calculated by a Kruskal-Wallis test with Dunn’s multiple comparison test, n = 44-55. Violin 
plots show median values and upper and lower quartiles, with an average of 10 images analysed per 
mouse. All data shows mean values ± SD. 
Figure 5. ITP progression increases BM CXCL12 expression and is associated with increased 
progenitor homing. Ai) BM Cxcl12 expression (control vs 2 week ITP P > 0.99, control vs 4 week 
ITP *P = 0.021, control vs 4 week ITP Recovered P > 0.99, 2 week ITP vs 4 week ITP P = 0.14, 4 
week ITP vs 4 week ITP Recovered P = 0.43). N = 4-6 (1-2 independent experiments), P values were 
calculated by a Kruskal-Wallis test with Dunn’s multiple comparison test. Aii) Spleen Cxcl12 
expression (P = 0.82). N = 6 (2 independent experiments). P value was calculated by a Mann-
































































































































with sustained ITP vs controls. C) CXCL12 ELISA using: i) BM supernatant (**P = 0.0023, N = 7), ii) 
spleen homogenate (P = 0.38, N = 7), iii) and plasma (P = 0.23, N = 3-4). 2 independent experiments, 
P values were calculated by Mann-Whitney tests. D) Experimental outline for E. E) Homing of naïve 
progenitors to the BM of mice with 4 week ITP vs controls (P = 0.004, N = 8-9). 2 independent 
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